Pharma Archives - Page 20 of 83 - Life Sciences Times

Strand Therapeutics Promotes Prashant Nambiar to Chief Scientific Officer and Appoints Ethan Cash as Senior Vice President, Head of Portfolio Management and Program Development

November 5, 2025

Pan-Mass Challenge Donates Record $78 Million to Dana-Farber Cancer Institute

November 3, 2025

Thermo Fisher Scientific to Acquire Clario Holdings, Inc., Expanding Clinical Data Capabilities to Accelerate Drug Development

October 29, 2025

THIS WEEK'S STORIES

Viridian Therapeutics Submits Biologics License Application to FDA for Veligrotug in Thyroid Eye Disease

November 3, 2025

athenahealth Unveils AI-Native Clinical Encounter to Transform the EHR into a Real-Time Clinical Intelligence Partner

November 4, 2025

Ensoma Presents Preclinical Data Highlighting Potential of In Vivo, HSC-Derived CAR-M, NK, and T Platform for Solid Tumors at SITC 2025

November 4, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Pharma

AstraZeneca Reports Positive Phase III NATRON Results Showing FASENRA Delayed Disease Worsening in Hypereosinophilic Syndrome

Astria Therapeutics Reports Final Positive Results from All Enrolled HAE Patients in ALPHA-STAR Phase 1b/2 Trial of Navenibart

Calluna Pharma Receives U.S. FDA Orphan Drug Designation for CAL101 in Idiopathic Pulmonary Fibrosis

Delix Therapeutics Reports Positive Phase Ib Results for Zalsupindole and FDA Clearance for Phase II Trial with At-Home Administration

Corsera Health Files First Phase 1 Clinical Trial Application for Preventive RNAi Medicine Targeting Cardiovascular Disease

Most Read

Arena BioWorks to Shut Down Amid Challenging Biotech Market Conditions

A2 Biotherapeutics Presents Initial EVEREST-2 Data, Including First Complete Response to CAR T-Cell Therapy in a Patient with NSCLC

Dechra Becomes Human-Animal Bond Certified Company to Support Veterinarians and Public Health